OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -3.70% | -2.80% | -19.38% |
20/05 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
14/05 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.38% | 151M | |
+43.64% | 754B | |
+40.25% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+8.78% | 298B | |
+18.38% | 250B | |
+12.27% | 217B | |
-0.61% | 216B | |
+6.13% | 164B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024